DAFTAR PUSTAKA

Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, McDonnell DP.
Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of
human hematopoietic stem cells. Proc Natl Acad Sci USA 2006;31:1170711712.
Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence
in patients treated for localized prostatecancer: the American Urological Association
Prostate Guidelines for Localized Prostate Cancer Update Panel report and
recommendations for a standard in the reporting of surgical outcomes. J Urol
2007;177:540545.
Collins, A. T., Habib, F. K., Maitland, N. J. and Neal, D. E. Identification and isolation of
human prostate epithelial stem cells on alpha(2)beta(1)-integrin expression. J. Cell Sci.
2001;114:3865-3872.
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of
tumorigenic prostate cancer stem cells. Cancer Res 2005;65:1094610951.
Duester G. Families of retinoid dehydrogenases regulating vitamin A function: production of
visual pigment and retinoic acid. Eur J Biochem 2000;267:43154324.
Eble JN, sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the
urinary sytem and male genital organs. IARC Press. Lyon. 2004.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN, Cancer
Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France:
International Agency for Research on Cancer. 2012.
Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and
malignant human colonic stem cells (SC) and tracks SC overpopulation during colon
tumorigenesis. Cancer Res 2009;69:33829.
Li T., Su Y., Mei Y., Leng Q., Leng B., Liu Z., Stass S.A., Jiang F. ALDH1A1 is a marker
for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab
Invest 2009;90:234-244.
Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M,
Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli
GC. Characterization and clinical relevance of ALDHbright populations in prostate
cancer. Clin Cancer Res 2013; 19(19): 53615371
Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of
cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood
1996;87:10971103.
Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44(+) prostate
cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic
progenitor cells. Oncogene 2006;25:1696 708.

Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, Bonnet D.
Characterization of cells with a high aldehyde dehydrogenase activity from cord blood
and acute myeloid leukemia samples. Stem Cells 2005;23:752760.
Sladek NE, Kollander R, Sreerama L, Kiang DT (2002) Cellular levels of aldehyde
dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to
cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational
individualization of oxazaphosphorine-based cancer chemotherap. Cancer Chemother
Pharmacol 49: 309321.
Sophos NA, Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2002 update. Chem
Biol Interact 2003:143144. 522.

Ucar D, Cogle CR, Zucali JR, et al. Aldehyde dehydrogenase activity as a functional marker
for lung cancer. Chem Biol Interact 2009;178: 4855.
Van Den Hoogen C., Van Der Horst G., Cheung H., Buijs J.T., Lippitt J.M., GuzmanRamirez N., Hamdy F.C., Eaton C.L., Thalmann G.N., Cecchini M.G., Pelger R.C.M.,
Van Der Pluijm G. High aldehyde dehydrogenase activity identifies tumor-initiating and
metastasis-initiating cells in human prostate cancer Cancer Research, 2010;70:51635173.
Yoshida A, Rzhetsky A, Hsu LC, Chang C. Human aldehyde dehydrogenase gene family. Eur
J Biochem 1998;251:549557.